Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

184
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
184
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

216
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
216
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

158
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
158
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

168
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
168
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

166
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

183
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives.

Circulation·2026
Same author

Placental Growth Factor Promotes Endothelial Activation and Inflammatory Remodelling in Pulmonary Hypertension.

Cardiovascular research·2026
Same author

Nurse-Led, Technology-Based Interventions to Improve Self-Care in Heart Failure Patients After Hospital Discharge: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

European journal of cardiovascular nursing·2026
Same author

Fenfluramine-associated pulmonary hypertension: a study of adverse events reporting system FAERS.

ERJ open research·2026
Same author

Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension.

ERJ open research·2026
Same author

Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension.

Science translational medicine·2026

相关实验视频

Updated: Jul 6, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K

肺高血压是一种肺高血压.

Ana Mocumbi1,2, Marc Humbert3,4, Anita Saxena5

  • 1Faculdade de Medicina, Universidade Eduardo Mondlane, Maputo, Moçambique. ana.mocumbi@uem.ac.mz.

Nature reviews. Disease primers
|January 4, 2024
PubMed
概括

肺高血压 (PH) 涉及肺动脉中的高血压,影响全球1%的人. 早期诊断和管理对于预防右心室衰竭至关重要,这是死亡的主要原因.

更多相关视频

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.2K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.8K

相关实验视频

Last Updated: Jul 6, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.2K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.8K

科学领域:

  • 心脏病学 心脏病学
  • 肺部病理学 肺部病理学
  • 血管医学 血管医学

背景情况:

  • 肺高血压 (PH) 是一组症状,其特征是肺动脉压力升高 (>20 mmHg平均值).
  • 它影响全球至少1%的人口,在低收入和中等收入国家存在显著差异.
  • PH涉及血管重塑,导致阻塞,硬化和血管收缩,最终导致右心室衰竭.

研究的目的:

  • 提供五个已知的肺高血压组的全面概述.
  • 突出PH的病理生理学,临床表现,诊断方法和目前的PH的管理策略.
  • 识别知识缺口并强调需要进一步研究,特别是在弱势群体中.

主要方法:

  • 根据病因和诊断标准将PH分为五组.
  • 对PH的流行病学,病理生理学和临床表现的审查.
  • 诊断途径的总结,包括右心脏导管.
  • 已批准和新兴的治疗策略的概述,针对潜在原因.

主要成果:

  • 确定了五个不同的PH群体,患病率各不相同 (例如,左侧心脏病的PH非常常见,PH动脉高血压很少见).
  • 呼吸不良是一种常见的症状,特别是在老年人中.
  • 右心室缩和衰竭是死亡的主要原因.
  • 肺动脉高血压和慢性血栓栓塞性肺高血压存在有效的治疗方法,其他形式的研究正在进行中.

结论:

  • 肺高血压是一种严重的疾病,有多种原因和显著的死亡率,主要是由于右心室衰竭.
  • 目前的管理重点是治疗潜在原因,为特定的PH类型制定了治疗方法.
  • 仍然存在大量的研究缺口,需要进一步研究以改善所有PH形式的表征,检测和治疗,特别是在服务不足的人群中.